Sagimet Biosciences
CompanyUnited States
Sagimet Biosciences develops one asset, in phase 3 (denifanstat in acne vulgaris). Mostly small molecule acting on lipid and ceramide metabolism and FASN; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 3
- 1
- Trial
- 2
- Signals
Pipeline
1Inhibits fatty acid synthase, reducing de novo fatty acid synthesis.
Phase 3, Small molecule, Lipid and ceramide metabolism, FASN, acne vulgaris
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- Signals2
- Similar companies6